Safety and Efficacy of SC101 Via Perirenal Fat Injection for Resistant Hypertension in Patients With Moderate to Severe Chronic Kidney Disease

Exclusion Criteria

• •Obvious pseudo-resistant hypertension caused by white-coat effect, incorrect BP measurement, poor medication adherence, use of drugs affecting antihypertensive efficacy, insufficient dosage, unreasonable combination therapy, or secondary hypertension (except obstructive sleep apnea) as judged by the investigator.
• •Confirmed history of secondary hypertension (including but not limited to renal artery stenosis, primary aldosteronism, pheochromocytoma, aortic coarctation, etc.).
• •Congenital renal abnormalities that may affect the safety and/or efficacy evaluation of the trial, including but not limited to solitary kidney or polycystic kidney disease.
• •Cardiovascular-related diseases that may affect safety evaluation, including but not limited to: uncontrolled symptomatic tachyarrhythmia or bradyarrhythmia (e.g., untreated persistent atrial fibrillation, second-degree or higher heart block, sick sinus syndrome); congestive heart failure NYHA Class III or IV; myocardial infarction, unstable angina, cerebrovascular accident, or transient ischemic attack within the past 6 months; severe structural heart disease (including moderate or higher valvular lesions, cardiomyopathy, congenital heart disease).
• •Abnormal liver function, defined as Alanine Aminotransferase (ALT) or Aspartate Aminotransferase (AST) \> 2 times the Upper Limit of Normal (ULN).
• •Hematological diseases that may affect safety evaluation, including but not limited to anemia (Hemoglobin \< 90 g/L) or abnormal coagulation function (INR \> 1.5 or fibrinogen less than the lower limit of normal).
• •Type 1 diabetes mellitus or poorly controlled hyperglycemia at screening (defined as HbA1c ≥ 7.5%).
• •Urinary system diseases requiring surgical intervention at screening.
• •Conditions unable to tolerate perirenal fat injection under local anesthesia, including but not limited to local skin problems or structural abnormalities adjacent to perirenal fat.
• •Contraindications related to anesthetics (such as lidocaine).
• •Life expectancy \< 1 year.
• •History of malignant tumors (except those cured for more than 5 years without recurrence) or confirmed malignant tumors or precancerous lesions.
• •Known Acquired Immunodeficiency Syndrome (AIDS) or HIV-positive status, or previous diagnosis of immunodeficiency with absolute neutrophil count \< 1000/mm\^3.
• •Active liver disease participants, such as positive HAV antibody, positive HBV markers (HBsAg, HBsAb, HBeAg, HBeAb, HBcAb, HBV DNA quantification), or positive HCV antibody (HCV Ab) and HCV RNA quantification above the detection limit.
• •Positive Syphilis antibody and positive Rapid Plasma Reagin (RPR) test.
• •Vaccination with live (attenuated) vaccines within 4 weeks before screening or planned during the trial.
• •Currently participating in other clinical trials, or received other interventional clinical trial drugs within 3 months prior to enrollment.
• •Currently using corticosteroids or immunosuppressants, where the investigator judges that dose adjustments will be required during the trial.
• •Women who are breastfeeding.
• •Other conditions that the investigator believes may affect compliance or make the participant unsuitable for the study.